Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Hot Flashes
Interventions: Paced respiration, Sham comparator: fast shallow breathing; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pharmacokinetics
Interventions: PrimeC-ER 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg; Drug
Lead sponsor: NeuroSense Therapeutics Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Blood Coagulation Disorders, Acute Major Bleeding
Interventions: Beriplex® P/N (Kcentra), Fresh frozen plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • San Franciso, California + 33 more

Conditions: Central Nervous System Lymphoma
Interventions: Methotrexate, Rituximab, leucovorin, Glucarpidase; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Boston, Massachusetts • Basking Ridge, New Jersey + 8 more

Conditions: Renal Insufficiency
Interventions: Abiraterone acetate: participants with end-stage renal disease, Abiraterone acetate: matched control participants with normal renal function; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Hiv, Diabetes Mellitus, Type 2
Interventions: Subcutaneous adipose tissue biopsy, CT scan, Oral glucose tolerance test, Blood collection; Procedure · Radiation · Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Critical Illness, Hypoxia, Respiratory Failure
Interventions: End-tidal oxygen monitor; Device
Lead sponsor: Sydney Local Health District; Government
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Albuquerque, New Mexico • The Bronx, New York

Conditions: Lactose Intolerance
Interventions: RP-G28; Drug
Lead sponsor: Ritter Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sleep Phase Rhythm Disturbance, Sleep Deprivation
Interventions: Morning Light Therapy, Assigned Sleep Times, Goggles; Behavioral · Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Status Asthmaticus, Asthma
Interventions: Montelukast, Sterile water; Drug · Other
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 5 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 1 Diabetes
Interventions: LY900014, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia • West Des Moines, Iowa • Minneapolis, Minnesota

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more

Conditions: Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma
Interventions: TMZ, E7016; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pharmacokinetics, Drug Interactions
Interventions: Dasatinib ASD, Omeprazole 40 MG; Drug
Lead sponsor: Xspray Pharma AB; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Pulmonary Arterial Hypertension
Interventions: treprostinil, Crono Five ambulatory pump; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Francisco, California • New York, New York • Oklahoma City, Oklahoma

Conditions: Sepsis, Systemic Inflammatory Response Syndrome, Infection Mixed, Infection, Bacterial, Infection, Fungal, Infection, Coronavirus, Antibiotic Resistance Genes, Human Genome Analysis
Interventions: Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly); Device
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2032
U.S. locations: 2
States / cities: Lansing, Michigan

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Microbiome Analysis, Metabolomics
Interventions: Freeze-dried blueberry powder beverage; Other
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Pain
Interventions: Desmetramadol; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg; Drug
Lead sponsor: Banner Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Septic Shock
Interventions: GIK; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Focal Segmental Glomerulosclerosis
Interventions: LIPOSORBER® LA-15; Device
Lead sponsor: Kaneka Medical America LLC; Industry
Eligibility: Up to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 10
States / cities: Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more

Conditions: Resistance Training, Breakfast
Interventions: Breakfast omission, Breakfast consumption; Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lubbock, Texas

Search by objective public record fields.

Breathe for Hot Flashes Randomized Controlled Trial

A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function

The HIV, Adipose Tissue Immunology, and Metabolism Study

End-Tidal Oxygen for Intubation in the Emergency Department

Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects

Are Bright Lights and Regulated Sleep Effective Treatment for Depression?

Montelukast With Status Asthmaticus, Ages 2-5

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites

A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

Rapid Administration of Insulin in Sepsis

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

The Effect of Breakfast Consumption on Afternoon Resistance Training Performance